Holen Sie sich die Stockscreener-App
271.63
1.72%
4.58
Handel nachbörslich:
271.63
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$267.05
Offen:
$267.05
24-Stunden-Volumen:
1.50M
Relative Volume:
1.41
Marktkapitalisierung:
$39.57B
Einnahmen:
$5.40B
Nettoeinkommen (Verlust:
$1.49B
KGV:
26.85
EPS:
10.1168
Netto-Cashflow:
$1.78B
1W Leistung:
+5.16%
1M Leistung:
+9.01%
6M Leistung:
-3.15%
1J Leistung:
+14.52%
1-Tages-Spanne:
$267.03
$272.33
1-Wochen-Bereich:
$250.54
$272.33
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
271.63 | 38.90B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
488.15 | 169.16B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
210.02 | 58.84B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
MDLN
Medline Inc
|
47.30 | 38.45B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
ALC
Alcon Inc
|
78.83 | 38.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Insider Sell: Michael Rider Sells Shares of ResMed Inc (RMD) - GuruFocus
Resmed: global general counsel Rider sells $13,000 in stock - Investing.com
Resmed director Farrell sells $502k in stock By Investing.com - Investing.com India
ResMed (NYSE:RMD) General Counsel Sells $13,000.00 in Stock - MarketBeat
ResMed (NYSE:RMD) Director Sells $502,620.00 in Stock - MarketBeat
Smart Sand, Inc. Achieves 140.93% Return, Outperforming NetApp and ResMed - Markets Mojo
RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand - TradingView
ResMed Chief Legal Officer Sells 50 Common Shares Of Firm - marketscreener.com
ResMed Director Sells 2,000 Shares - marketscreener.com
Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today - The Motley Fool Australia
ResMed Inc (RMD) Stock Price Down 0% on Feb 5 - GuruFocus
The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call - The Globe and Mail
The Top 5 Analyst Questions From ResMed's Q4 Earnings Call - Finviz
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from UBS - The Globe and Mail
ResMed Deepens CPAP Lead As Wearables And Digital Tools Expand Reach - Yahoo Finance
ResMed Adjusts CDI and Share Balances Amid Ongoing Capital Management - TipRanks
What can investors expect from ResMed, Cochlear and CSL shares this reporting season? - The Motley Fool Australia
Allianz Asset Management GmbH Acquires 110,647 Shares of ResMed Inc. $RMD - MarketBeat
WCM Investment Management LLC Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Slipped 1% on Profit Beat: Is $400 the 2026 Recovery Target? - TIKR.com
The Truth About ResMed Inc.: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
ResMed At Wearable And AI Turning Point In Sleep Apnea Care - Sahm
Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells 1,000 Shares Under Pre-Set Trading Plan - TipRanks
ChartWatch ASX Scans: Appen, Aussie Broadband, Flight Centre Travel, Resmed, Siteminder, Sunrise Energy Metals - Market Index
Resmed Founder Receives 2026 Horatio Alger Award - respiratory-therapy.com
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions - Yahoo Finance
Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge - Yahoo Finance
ResMed Inc. (RMD): A Bull Case Theory - Finviz
Ord Minnett Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed Inc. (RMD) Stock Analysis: A Strong Performer With 15% Upside Potential - DirectorsTalk Interviews
ResMed (RMD) Rating Maintained by Citigroup as Price Target Rises | RMD Stock News - GuruFocus
ResMed Bull Anticipates Further Buybacks -- Market Talk - 富途牛牛
National Pension Service Grows Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Bought by Mediolanum International Funds Ltd - MarketBeat
Morgans Financial Upgrades ResMed to Buy from Accumulate, Price Target is AU$47.73 - marketscreener.com
Portfolio Shifts: How volatile is ResMed Inc stock2025 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
ResMed outlines 62%–63% gross margin target for fiscal 2026 amid double-digit growth in key segments - MSN
ResMed Inc Earnings Call Shows Profitable Growth Momentum - TipRanks
ResMed Bull Stays Positive Amid Strong Revenue Growth -- Market Talk - 富途牛牛
ResMed: Interim result 2026 - intelligentinvestor.com.au
ResMed Files Quarterly Form 10-Q for December 2025 - TipRanks
ResMed Inc. $RMD Shares Acquired by Keybank National Association OH - MarketBeat
ResMed: Facing A Potentially Dream-Disrupting DoseStrong Sell - Seeking Alpha
ResMed (RMD) Net Margin Strength In Q2 2026 Supports Bullish Earnings Narrative - Sahm
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
ResMed Reaffirms 2025 Risk Profile: No Material Changes to Previously Disclosed Threats - TipRanks
Is Federal Agricultural Mortgage Corporation stock trending bullishGap Down & Technical Pattern Based Buy Signals - baoquankhu1.vn
RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth - Finviz
KeyBanc raises ResMed stock price target to $302 on solid revenue beat - Investing.com UK
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):